Dijabetesna retinopatija je najčešća mikrovaskularna komplikacija šećerne bolesti i jedna je od vodećih uzroka slepila kod odraslih uzrasta 20-74 godina. Učestalost mikrovaskularnih komplikacija dijabetesa je jasno povezana sa trajanjem dijabetesa, kvalitetom metaboličke kontrole i sistolnim krvnim pritisakom. Cilj rada bio je da se utvrdi incidencija i odrede karakteristike faktora rizika za razvoj retinopatije kod bolesnika sa dijabetesom tip 2. Studija je obuhvatila 100 ispitanika sa dijabetes melitusom tip 2, prosečne starosti 61,95±3, 98 godina. Pacijenti su podeljeni u dve grupe: pacijenti sa dijabetesom tip 2, na terapiji oralnim antidijabeticima, činili su grupu I, pacijenti sa dijabetesom tip 2 na kombinovanoj terapiji činili su grupu II. Analizirali smo anamnestičke podatke, stil života i porodičnu istoriju, štetne navike pre svega pušenje. Od kliničkih karakteristika utvrđena je telesna masa, visina, obim struka, arterijski pritisak, urađene su standardne biohemijske analize. Dijagnoza dijabetesne retinopatije postavljena je na os- novu modifikovane Međunarodne klasifikacije retinopatija. Ispitanici studijske grupe II, imali su statistički značajno duže trajanje bolesti u odnosu na ispitanike kontrolne grupe (p<0,001). U odnosu na antropometrijske karakteristike, ispitivane grupe se statistički nisu razlikovale (ITM, 27,28±8,28kg/m2 vs 28,72±5,75 kg/m2; t-1,306, a p=0,197, obim struka 95,70±12,96cm vs 94,58±12,96cm). Srednje vrednosti sistolnog krvnog pritiska u studijskoj grupi II bile su 144,50±27,37 a dijastolnog 86,30±11,08 mmHg, a u grupi koja je bila na oralnim hipoglikemicima 137,00±27,37mmHg za sistolni a dijastolnog 83,11 ±10,08 mmHg, r-0,00, p=1,00, nije bilo statistički značajne razlike među grupama. Bolesnici studijske grupe II nisu imali značajno veće vrednosti holesterola (6,02±1,59 vs 5,73± 1,29mmol/L; p=0,501), LDL holesterola (3,75±1,35 vs 3,94±1,21mmol/L; p=0,55), HDL holesterola (1,14±0,61 vs 1,02±0,27mmol/L; p=0,005), glikemije (10,2±8,15 vs 9,2±1,4mmol/L; p=0,183), u odnosu na grupu I, dok su vrednosti triglicerida su bile značajno veće (2,49±2,03 vs 2,00±1,22mmol/L; p=0,01). Poređenjem vrednosti HbA1c, statistički značajna razlika nije ustanovljena (8,8% vs 7,8%; t-2,946, p=0,009). Faktori rizika za razvoj retinopatije kod pacijenata sa dijabetesom tip 2 bili su značajno zastupljeni u obe ispitivane grupe.
Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA. 2007;298(8):902–16.
2.
Kaplan NM. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine. 1989;149(7):1514–20.
3.
Kaštelan S, Tomić M, Kuzmanović-Elabjer B, Rotkvić L. The role of angiotensin-converting enzyme inhibitors in the pathogenesis of diabetic retinopathy. Diabetologia Croatica. 2007;36:3–9.
4.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801–15.
5.
Ko S, Cao W, Liu Z. Hypertension management and microvascular insulin resistance in diabetes. Current Hypertension Reports. 2010;12(4):243–51.
6.
Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes. 1982;31(1):19–21.
7.
L’Esperance FA. Ophthalmic laser: Photocoagulation, photoradiation and surgery. St Louis. 1982;C. V.
8.
Lövestam-Adrian M, Agardh C, Torffvit O, Agardh E. Type 1 diabetes patients with severe non-proliferative retinopathy may benefit from panretinal photocoagulation. Acta Ophthalmologica Scandinavica. 2003;81(3):221–5.
9.
Mahar PS, Awan ZM, Manzar N, Memon SM. Prevalence of type II diabetes mellitus and diabetic retinopathy: The Gaddap study. Journal of the College of Physicians and Surgeons Pakistan. 2010;20(8):528–32.
10.
Mavrikakis E, Lam WC, Khan BU. Macular edema, diabetic: Treatment and management. 2011;
11.
12.
Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35(3):592–6.
13.
Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic retinopathy. Diabetes Care. 1991;14(2):119–26.
14.
Novaković T. Statini – lekovi izbora za lečenje poremećaja metabolizma masti kod bolesnika sa dijabetesom tip 2. Praxis Medica. 2005;33(1–2):95–6.
15.
Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and strokes. Kidney International. 2002;61(3):1086–97.
16.
Šarenac T. Savremeni principi lečenja dijabetske retinopatije. Medicinski časopis. 2011;45(3):27–31.
17.
Group UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837–53.
18.
Wong TY, Klein R. Diabetic retinopathy in a multiethnic cohort in the United States. American Journal of Ophthalmology. 2006;141:446–55.
19.
Organization WH. Obesity: Preventing and managing the global epidemic. In: Report of WHO Consultation on Obesity, Geneva. 1997. p. 7–17.
20.
Organization WH. Definition, diagnosis and classification of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. 2006.
21.
Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: A cohort study. Lancet. 2003;361(9353):195–200.
22.
Group ETDRR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. Ophthalmology. 1991;98(Suppl.):786–806.
23.
Association WM. Helsinška deklaracija. 1954;
24.
2012;
25.
The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine. 1993;329(14):977–86.
26.
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000;321(7258):412–9.
27.
Association AD. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2002;25(Suppl. 1):5–20.
28.
Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl. 1):64–71.
29.
Basteau F, Mortemousque B, Verin P, Barac’h D, Dorot M, Chraibi-Asseini K. Nouvelle technique de photocoagulation des rétinopathies diabétiques non prolifératives sévères. Journal Français d’Ophtalmologie. 1998;21(2):83–93.
30.
Borch-Johnsen K. Epidemiology of microangiopathy in type 1 diabetes mellitus: A review. Diabetes & Metabolism. 1993;19:133–7.
31.
Chew EY, Klein ML, Ferris F, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology. 1996;114(9):1079–84.
32.
del Cañizo Gómez FJ, Fernández Pérez C, Moreno Ruiz I, de Gorospe Pérez-Jáuregui C, Silveira Rodríguez B, González Losada T, et al. Microvascular complications and risk factors in patients with type 2 diabetes. Endocrinología y Nutrición. 2011;58(4):163–8.
33.
Subcommittee G. 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension. 1999;17(2):151–85.
34.
Group ETDRSR. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology. 1987;number 2:761–74.
35.
Detection EP. Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285(19):2486–97.
36.
Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540–53.
37.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2011;29(3):116–22.
38.
Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 years before clinical diagnosis. Diabetes Care. 1992;15(7):815–9.
39.
Holman RR, Paul SK, Bethel AM, Matthews DR, Neil H. 10-Year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine. 2008;359(15):1577–89.
40.
Hove MN, Kristensen JK, Lauritzen T, Bek T. The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes. Acta Ophthalmologica Scandinavica. 2006;84(5):619–23.
41.
Inić KB, Božanić L, Novaković T, Đokić N, Đokić A, Trajković S, et al. Uticaj loše metaboličke kontrole na progresiju i razvoj dijabetične retinopatije u insulin nezavisnom dijabetesu melitusu tip 2. Praxis Medica. 2011;39(1–2):81–4.
42.
Jarrett RJ. Duration of non–insulin-dependent diabetes and development of retinopathy: Analysis of possible risk factors. Diabetic Medicine. 1986;3(3):261–3.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
